4523.TO

Researchers released new details from a study of a closely watched drug for Alzheimer’s disease on Tuesday, shedding more light on the drug’s risks and benefits as U.S. health regulators weigh approving it.  Eisai Co. and Biogen Inc.’s drug, called lecanemab, slowed cognitive decline by 27% compared with a placebo over 18 months in a study of more than 1,700 people with early-stage Alzheimer’s, researchers reported in the New England Journal of Medicine on…

An experimental Alzheimer’s drug from Roche Holding AG failed to significantly slow cognitive decline in long-awaited trials, the latest in a long line of setbacks for a field that has seen little progress in decades. The drug, called gantenerumab, slightly reduced cognitive decline in people with early Alzheimer’s compared with a placebo across two large and lengthy trials, but the difference wasn’t statistically significant, Roche said Monday. The trials,…

Strong recent study results for an experimental Alzheimer’s treatment have exposed a gap between the changes such drugs can make in the brain and their potential limits in alleviating symptoms of the debilitating disease.Lecanemab cleared accumulations in the brain of beta-amyloid, sticky protein fragments that researchers have long suspected contribute to Alzheimer’s, drugmakers Biogen Inc. BIIB -1.21% and Eisai Co. ESALY 0.17%…

The pharmaceutical companies said their drug lecanemab reduced cognitive and functional decline by 27%, compared with a placebo, over 18 months in a Phase 3 study of 1,800 patients with early-stage Alzheimer’s. The drug was also linked to higher rates of brain swelling and small bleeds, though the company said they were rarely symptomatic. “Today’s announcement gives patients and their families hope that lecanemab, if approved, can potentially slow the progression of Alzheimer’s disease, and provide a clinically…